Erythropoietin: is it more than correcting anaemia?
نویسندگان
چکیده
21st May 2003 21. Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762 22. Trenkwalder P. Kalziumantagonisten zut Hypertoniebehandlung. Muench Med Wschr-Fortsch Med 2001; 43: 567–568
منابع مشابه
Recombinant human erythropoietin in oncology: current status and further developments.
Anaemia effects up to 90% of cancer patients, with more than 60% requiring blood transfusion during or after treatment. With the advent of recombinant human erythropoietins (rHuEPO), an alternative to red blood cell transfusion has become available. So far, three drugs have been approved for the treatment of anaemia in patients with malignancies (epoetin alfa, epoetin beta and darbepoetin alfa)...
متن کاملDialysis: its role in optimizing recombinant erythropoietin treatment.
Although iron deficiency is probably the most important factor affecting response to recombinant erythropoietin (Epo, epoetin), other factors are of significance, including dialysis adequacy. Additionally, water treatment and distribution, sterilizants and the quality of the dialysate in terms of trace elements (particularly chloramine) are of importance in relation to erythropoiesis inhibition...
متن کاملClinical significance of serum IL-6, TNF-α, Hepcidin, and EPO levels in anaemia of chronic disease and iron deficiency anaemia: The laboratory indicators for anaemia
Background: Pathogenesis of anaemia of chronic disease is multifactorial. It is related with corrupted erythropoietin-dependent erythropoiesis due to C-reactive protein, and pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha. It is also related with decreased red cell survival and impaired iron mobilization. Hepcidin level in iron deficiency anaemia is low than co...
متن کاملContribution of anaemia to progression of renal disease: a debate.
It is hypothesized that anaemia contributes to the progression of renal disease via hypoxia and oxidative stress. These effects may stimulate the production of extracellular matrix by fibroblasts, increasing interstitial fibrosis and leading to tubular destruction. Recombinant human erythropoietin (r-HuEPO, epoetin) has antioxidative and anti-apoptotic properties, though these effects have yet ...
متن کاملCost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
OBJECTIVE To assess the cost benefits of low dose subcutaneous recombinant human erythropoietin in correcting the anaemia of end stage renal disease. DESIGN Three year retrospective study. SETTING Subregional nephrology service serving a mixed urban and rural population of 800,000. SUBJECTS 60 patients with symptoms of anaemic end stage renal disease treated with erythropoietin (43 receiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
دوره 19 1 شماره
صفحات -
تاریخ انتشار 2004